MC
SAGE

Matisse Capital’s Sage Therapeutics SAGE Stock Holding History

Matisse Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,500
Closed -$391K – 130
2018
Q2 		$391K Buy
2,500
+1,000
+67% +$157K 0.31% 73
2018
Q1 		$242K Buy
+1,500
New +$255K 0.15% 108

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Matisse Capital's SAGE Position: Q3 2018 in Review

Matisse Capital sold out of Sage Therapeutics (SAGE) in Q3 2018, closing a stake of 2,500 shares — an estimated $391K sold.

Matisse Capital first reported a position in SAGE in Q1 2018 and held it in 2 quarters. The position peaked at $391K in Q2 2018. 275 funds tracked by Wall St. Rank hold SAGE as of Q3 2018.

  • Matisse Capital reported no remaining Sage Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Matisse Capital sold 2,500 Sage Therapeutics shares in Q3 2018, an estimated $391K.
  • Matisse Capital first reported a position in Sage Therapeutics in Q1 2018 and held it in 2 quarters.
  • Matisse Capital's Sage Therapeutics position peaked at $391K in Q2 2018.
  • 275 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2018.

Based on Matisse Capital's 13F filing for Q3 2018, filed 30 Oct 2018.